This Startup Wants To Catch Cancer Before It Spreads
Y Combinator Startup PodcastFull Title
This Startup Wants To Catch Cancer Before It Spreads
Summary
Billion2One, a molecular diagnostics company, has developed a revolutionary approach to detecting rare DNA fragments in blood for both prenatal testing and cancer detection. The company's innovative method, which addresses the "needle in a haystack" problem of identifying minute DNA signals amidst vast amounts of other DNA, has led to significant commercial success and a path towards potentially changing the landscape of cancer screening.
Key Points
- Billion2One's core innovation lies in its ability to accurately detect rare DNA fragments in blood samples, a challenge previously deemed insurmountable due to the low concentration of target DNA and the "noise" introduced by amplification processes.
- The company initially focused on prenatal genetic testing, developing a widely adopted test that detects fetal DNA in maternal blood, thereby avoiding invasive procedures. This success provided the foundation and resources for tackling more complex diagnostic challenges.
- Billion2One is strategically expanding its technology to cancer diagnostics, starting with late-stage cancers via liquid biopsies and aiming for early-stage cancer detection, which is considered the "holy grail" of cancer screening.
- The rapid development and commercialization of their technology, from PhD students with limited resources to a publicly traded company processing over 600,000 tests annually, is attributed to their interdisciplinary approach and iterative development cycle.
- The company faced significant early challenges in sales and market adoption, employing creative strategies like direct-to-patient marketing to drive physician adoption of their prenatal test.
- Billion2One has built a state-of-the-art lab leveraging AI and computer vision to streamline sample processing and has a clear, multi-step plan for future product development, mirroring ambitious growth strategies seen in other tech sectors.
- The company emphasizes hiring interdisciplinary scientists who can own end-to-end product development, fostering a culture of rapid iteration and problem-solving within small, autonomous teams.
Conclusion
Billion2One's innovative approach to DNA detection in blood has successfully addressed critical needs in prenatal diagnostics and is now poised to revolutionize cancer detection, aiming for early-stage screening as a major breakthrough in healthcare.
The company's rapid growth and success are a testament to their interdisciplinary hiring strategy, iterative development process, and a clear, ambitious roadmap for future product innovation.
The pursuit of challenging healthcare problems, like early cancer detection, requires a unique blend of scientific rigor, entrepreneurial drive, and a commitment to making diagnostics accessible and affordable.
Discussion Topics
- How can breakthroughs in genetic sequencing and bioinformatics be leveraged to tackle other complex diagnostic challenges beyond prenatal and cancer detection?
- What are the ethical considerations and regulatory hurdles involved in developing and deploying highly sensitive early cancer detection tests on a wide scale?
- How can startups in the healthcare innovation space balance the need for rapid technological advancement with the imperative to ensure affordability and accessibility for all patients?
Key Terms
- Cell-free DNA (cfDNA)
- Fragments of DNA that circulate in the bloodstream, released from various tissues, including fetuses and tumors.
- PCR (Polymerase Chain Reaction)
- A laboratory technique used to amplify small segments of DNA.
- Minimal Residual Disease (MRD) test
- A test designed to detect very small amounts of cancer cells remaining in the body after treatment.
- Liquid biopsy
- A non-invasive test that detects cancer markers in bodily fluids like blood, such as circulating tumor DNA (ctDNA).
- Interdisciplinary
- Involving or drawing together knowledge and methods from various disciplines.
- Quantitative Counting Templates (QCTs)
- Proprietary synthetic DNA used by Billion2One to quantify DNA amplification and identify errors.
- Microsatellite Instability (MSI)
- A condition in which the DNA repair mechanism is deficient, leading to changes in the length of short repeating DNA sequences.
Timeline
Billion2One's core innovation is detecting DNA in blood samples, including fetal and cancer DNA, enabling diagnostics previously impossible.
The company's foundational idea, conceived in 2017, was to create a universal prenatal genetic test using fetal DNA fragments from maternal blood, which was a radical concept at the time.
The key insight to overcome the challenge of detecting rare and dilute DNA fragments was the use of synthetic DNA to calibrate amplification processes and remove errors from sequencing data.
The founders, Ozan and David, met as undergraduates and later pursued PhDs before reconnecting to form Billion2One, achieving rapid development within two years.
The company's success was enabled by a recent development in sequencing technology and an interdisciplinary approach that bridges data science and chemistry.
Within six months of applying to YC, they developed a functional test and proved its accuracy, despite initial resource limitations and sharing lab space.
The initial fundraising was challenging, with the first $300,000 raised slowly and incrementally over six months.
Post-launch, initial adoption of the prenatal test was slow, with only one physician using it two months after release.
The company implemented an "emergency building" approach to sales, rapidly hiring and training a sales team to increase physician outreach.
Once the sales challenge was overcome, the company scaled up and built a state-of-the-art lab in 2022.
The lab process begins with logging and tracking samples, utilizing AI and computer vision to accelerate the accessioning process, now called "Accessioning in 60 Seconds."
After sample accessioning, samples are centrifuged to separate plasma containing cell-free DNA, which is then processed by liquid handling robots.
The company manufactures its own proprietary quantitative counting templates (QCTs) to measure and remove biases in the DNA amplification process.
A method of combining and sequencing multiple patient samples in a single droplet, identified by unique barcodes, allows for simultaneous analysis.
Post-sequencing, the process is entirely computational, with laboratory directors and genetic counselors analyzing results, though most are processed automatically.
Billion2One's core technology extends beyond prenatal testing to cancer detection through liquid biopsies, with an early version launched in 2023.
The company's roadmap began with prenatal genetics, progressing to late-stage cancers, and is now focused on early-stage cancer detection.
A compelling patient story highlights the impact of their cancer product, enabling a young patient with metastatic colorectal cancer to receive immunotherapy based on detecting microsatellite instability in their blood.
The company hires interdisciplinary scientists who can work independently and lead small research teams, directly reporting to the founders to accelerate development.
This structure creates "many startups within the larger company," with each team owning a product and iterating rapidly.
The company's three-step plan, starting with prenatal testing, then late-stage cancer, and finally early-stage cancer, mirrors ambitious growth strategies, with a key difference being the focus on accessibility and affordability in healthcare.
Step three of their plan involves using the technology to detect microscopic residual tumor DNA in patients with stage one and two cancers after surgery, a crucial step for preventing recurrence.
The ultimate goal is general cancer screening, enabling annual detection of early-stage cancers before they spread.
The step-by-step approach, enabled by initial success in prenatal testing, allowed them to develop complex cancer diagnostics without needing massive initial funding.
The company culture emphasizes that "pressure is a privilege," attracting individuals who are motivated by challenging work and the opportunity to make a significant impact on healthcare.
Episode Details
- Podcast
- Y Combinator Startup Podcast
- Episode
- This Startup Wants To Catch Cancer Before It Spreads
- Official Link
- https://www.ycombinator.com/
- Published
- April 6, 2026